ATE322912T1 - Radiomarkierte pyrimidinnukleoside zur diagnose von gewebe-reproduzierender aktivität - Google Patents

Radiomarkierte pyrimidinnukleoside zur diagnose von gewebe-reproduzierender aktivität

Info

Publication number
ATE322912T1
ATE322912T1 AT02716326T AT02716326T ATE322912T1 AT E322912 T1 ATE322912 T1 AT E322912T1 AT 02716326 T AT02716326 T AT 02716326T AT 02716326 T AT02716326 T AT 02716326T AT E322912 T1 ATE322912 T1 AT E322912T1
Authority
AT
Austria
Prior art keywords
denotes
radiom
substituent
pyrimidine nucleosides
denotes hydrogen
Prior art date
Application number
AT02716326T
Other languages
English (en)
Inventor
Jun Toyohara
Akio Hayashi
Original Assignee
Nihon Mediphysics Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nihon Mediphysics Co Ltd filed Critical Nihon Mediphysics Co Ltd
Application granted granted Critical
Publication of ATE322912T1 publication Critical patent/ATE322912T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT02716326T 2001-01-23 2002-01-22 Radiomarkierte pyrimidinnukleoside zur diagnose von gewebe-reproduzierender aktivität ATE322912T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2001014954 2001-01-23

Publications (1)

Publication Number Publication Date
ATE322912T1 true ATE322912T1 (de) 2006-04-15

Family

ID=18881578

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02716326T ATE322912T1 (de) 2001-01-23 2002-01-22 Radiomarkierte pyrimidinnukleoside zur diagnose von gewebe-reproduzierender aktivität

Country Status (14)

Country Link
US (2) US7045115B2 (de)
EP (1) EP1270017B1 (de)
JP (1) JP4210118B2 (de)
KR (1) KR100867729B1 (de)
CN (1) CN100400107C (de)
AT (1) ATE322912T1 (de)
AU (1) AU2002226690B2 (de)
CA (1) CA2402991C (de)
DE (1) DE60210538T2 (de)
HK (1) HK1059396A1 (de)
NO (1) NO328812B1 (de)
NZ (1) NZ520934A (de)
TW (1) TWI247609B (de)
WO (1) WO2002058740A1 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
EP1673353A4 (de) * 2003-09-05 2007-03-28 Einstein Coll Med Übergangszustandstruktur und inhibitoren von thymidinphosphorylase
WO2005027962A1 (en) * 2003-09-18 2005-03-31 Isis Pharmaceuticals, Inc. 4’-thionucleosides and oligomeric compounds
US7485283B2 (en) * 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
JP4841231B2 (ja) * 2005-11-07 2011-12-21 日本メジフィジックス株式会社 組織増殖能診断用薬剤
CA2649182C (en) 2006-04-07 2018-01-02 The Board Of Regents Of The University Of Texas System Methods and compositions related to adenoassociated virus-phage particles
US7928210B2 (en) 2007-03-01 2011-04-19 Siemens Medical Solutions Usa, Inc. Nucleoside based proliferation imaging markers
EP2155231B1 (de) * 2007-04-10 2012-08-08 The Johns Hopkins University Bilddarstellung und behandlung von virus-assoziierten tumoren
CA2967254C (en) * 2008-02-29 2019-03-26 Lantheus Medical Imaging, Inc. Contrast agents for applications including imaging cancer
GB0815831D0 (en) * 2008-09-01 2008-10-08 Imp Innovations Ltd Compounds
EP2419096B1 (de) 2009-04-15 2019-11-13 Lantheus Medical Imaging, Inc. Stabilisierung von radiopharmazeutischen zusammensetzungen mit ascorbinsäure
JP6092628B2 (ja) 2010-02-08 2017-03-08 ランセウス メディカル イメージング， インコーポレイテッド 造影剤およびその中間体を合成するための方法および装置
US8835612B2 (en) * 2010-10-09 2014-09-16 Fabio Polato Isolation of phosphoproteins, glycoproteins and fragments thereof
JP5794521B2 (ja) * 2011-03-29 2015-10-14 国立大学法人福井大学 アポトーシス誘導剤
SG11201406080VA (en) 2012-03-28 2014-11-27 Fujifilm Corp SALT OF 1-(2-DEOXY-2-FLUORO-4-THIO-β-D-ARABINOFURANOSYL)CYTOSINE
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
RU2633355C2 (ru) * 2012-08-13 2017-10-12 Фуджифилм Корпорэйшн СИНТЕТИЧЕСКОЕ ПРОМЕЖУТОЧНОЕ СОЕДИНЕНИЕ 1-(2-ДЕЗОКСИ-2-ФТОР-4-ТИО-β-D-АРАБИНОФУРАНОЗИЛ)ЦИТОЗИНА, СИНТЕТИЧЕСКОЕ ПРОМЕЖУТОЧНОЕ СОЕДИНЕНИЕ ТИОНУКЛЕОЗИДА И СПОСОБ ИХ ПОЛУЧЕНИЯ
JP2014062054A (ja) * 2012-09-20 2014-04-10 Gyoseiin Genshino Iinkai Kakuno Kenkyusho よう素−１２３標記チミン類似物［１２３Ｉ］−ＩａｒａＵのプローブ
JP6351107B2 (ja) * 2014-02-18 2018-07-04 富士フイルム株式会社 チオラン骨格型糖化合物の製造方法およびチオラン骨格型糖化合物
TWI678373B (zh) 2014-10-31 2019-12-01 日商富士軟片股份有限公司 硫代核苷衍生物或其鹽及醫藥組合物
WO2018043530A1 (ja) 2016-08-31 2018-03-08 富士フイルム株式会社 抗腫瘍剤、抗腫瘍効果増強剤及び抗腫瘍用キット
CA3089728C (en) 2018-01-29 2023-01-10 Fujifilm Corporation Antitumor agent for biliary tract cancer and method for treating biliary tract cancer
CN113683648A (zh) * 2021-08-26 2021-11-23 上海皓鸿生物医药科技有限公司 一种2’-氟-2’-脱氧尿苷的合成方法及其中间体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE74701B1 (en) * 1989-10-04 1997-07-30 Univ Birmingham Further antiviral pyrimidine nucleosides
US5077034A (en) 1990-03-30 1991-12-31 The President And Fellows Of Harvard College Treatment of tumors with 5-radioiodo-2'-deoxyuridine
US5248771A (en) 1991-06-26 1993-09-28 Triumf Process for preparing no-carrier-added radiohalogenated vinyl nucleosides
GB9421223D0 (en) 1994-10-21 1994-12-07 Univ Alberta Tissue imaging in gene therapy
US5574148A (en) 1995-02-02 1996-11-12 President U Fellows Of Harvard College Rapid synthesis of radiolabeled pyrimidine nucleosides or nucleotides
US5703056A (en) * 1995-03-15 1997-12-30 Sloan-Kettering Institute For Cancer Research Non-invasive imaging of gene transfer
US5720935A (en) * 1995-06-09 1998-02-24 President & Fellows Of Harvard College Rapid synthesis of radiolabeled pyrimidine nucleosides or nucleotides from stannyl precursors
WO1996041646A2 (en) 1995-06-13 1996-12-27 Dyer, Alison, Margaret Pharmaceutical compositions containing lornoxicam and cyclodextrin
US6331287B1 (en) 1995-08-23 2001-12-18 University Advanced Bio-Imaging Associates 2′-deoxy-2′-fluoro-d-arabinofuranosyl pyrimidine nucleoside
WO2001005439A1 (en) * 1999-07-14 2001-01-25 President And Fellows Of Harvard College Radiodetection and therapy of aberrant cell proliferation
KR200188038Y1 (ko) 2000-01-24 2000-07-15 이정진 전자파 피해가 감소되는 안테나 구조를 가진 휴대폰.

Also Published As

Publication number Publication date
TWI247609B (en) 2006-01-21
US7118731B2 (en) 2006-10-10
NZ520934A (en) 2004-12-24
CN100400107C (zh) 2008-07-09
WO2002058740A1 (fr) 2002-08-01
DE60210538T2 (de) 2006-10-05
DE60210538D1 (de) 2006-05-24
EP1270017B1 (de) 2006-04-12
US7045115B2 (en) 2006-05-16
US20050129611A1 (en) 2005-06-16
CA2402991A1 (en) 2002-08-01
CA2402991C (en) 2009-06-23
AU2002226690B2 (en) 2006-07-13
NO20024324D0 (no) 2002-09-10
US20030124054A1 (en) 2003-07-03
CN1455683A (zh) 2003-11-12
JP4210118B2 (ja) 2009-01-14
HK1059396A1 (en) 2004-07-02
NO328812B1 (no) 2010-05-18
JPWO2002058740A1 (ja) 2004-05-27
EP1270017A4 (de) 2004-04-28
KR100867729B1 (ko) 2008-11-10
NO20024324L (no) 2002-11-07
EP1270017A1 (de) 2003-01-02
KR20020084212A (ko) 2002-11-04

Similar Documents

Publication Publication Date Title
ATE322912T1 (de) Radiomarkierte pyrimidinnukleoside zur diagnose von gewebe-reproduzierender aktivität
PE20030601A1 (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y transtornos relacionados
RU2009143333A (ru) Производные аминодигидротиазина, замещенные циклической группой
DE602005024279D1 (de) 5-substituierte-2-phenylaminobenzamide als mek-inhibitoren
DK1131096T3 (da) Anti-CD20-antistofbehandling af patienter, der modtager knoglemarvs- eller periferisk blodstamcelletransplantationer
ID27531A (id) Penggunaan senyawa untuk peningkatan aktivitas piruvat dehidrogenase
BRPI0507180A (pt) derivados de 1-isopropil-2-oxo-1,2-diidropiridina-3-carboxamida tendo atividade agonìstica de receptor 5-ht4
TR200100410T2 (tr) 2-(purin-9-il)-tetrahidrofuran-3,4-diol türevleri.
GB0021831D0 (en) Chemical compounds
DE69626218D1 (de) 4-pyrimidinyl- or 4-pyrazinyl-piperazinyl-phenyl-oxazolidinon derivate, deren herstellung und deren verwendung als antibakterielle mittel
BR0002796A (pt) Compostos de 2-benzimidazolilamina como agonistas de receptores orl1
NO933452D0 (no) Et terapeutisk middel for parkinson's sykdom
ATE471323T1 (de) Purinderivate als antagonisten an purinergen rezeptoren
MXPA05012247A (es) Derivados de bencimidazol nuevos.
EA200100204A1 (ru) Фармацевтические агенты для лечения болезни паркинсона, ганв и микроаденом
DE60003220D1 (de) [1,2,3]-TRIAZOLO[4,5-d]PYRIMIDIN-DERIVATE ALS ANTITHROMBOTISCHE MITTEL
RU2008122401A (ru) Новые n-(фтор-пиразинил)-фенилсульфонамиды в качестве модуляторов хемокинового рецептора ccr4
DK283487D0 (da) Thiazolyl-2-yl-imidazo(1,2-a)pyrimidiner, deres fremstilling og brug
HUP0100102A2 (hu) Fenil-amino-alkilkarbonsav-származékok és fenil-amino-alkilkarbonsav-származékokat tartalmazó gyógyszerészeti készítmények
MY127036A (en) Substituted n-phenyl 2-hydroxy-2-methyl-3,3,3- trifluoropropanamide derivatives which elevate pyruvate dehydrogenase activity
EA200200095A1 (ru) Новые нафтилсульфоновые кислоты и родственные соединения в качестве агонистов поглощения глюкозы
MA28325A1 (fr) Nouveaux derives de phenylpyridinylpiperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
ATE330958T1 (de) Pyrazino 1'2':1,6öpyrido 3,4-böindolderivate
DE60031699D1 (de) Hydroxyacetamidobenzolsulfonamidderivate
BR112021012834A2 (pt) Derivados de pirimidina para a prevenção e tratamento de infecções bacterianas gram-negativas

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties